Topics discussed | N | Percent (%) |
---|---|---|
HPV-associated cancers | ||
Cervical cancer | 20 | 58.8 |
Oropharyngeal cancer | 8 | 23.5 |
Penile cancer | 7 | 20.6 |
Vulvar/vaginal cancer | 7 | 20.6 |
Anal cancer | 4 | 11.8 |
Effective date of mandate | 31 | 91.2 |
Number of doses that are recommended for complete HPV vaccination | 13 | 38.2 |
Concerns about the efficacy and safety of the vaccine | 19 | 55.9 |
Highlighted the importance of the vaccine for cancer prevention | 27 | 79.4 |
Referred to HPV as a STI | 9 | 26.5 |
Information regarding HPV vaccine accessibility and health coverage | 8 | 23.5 |
Groups Cited | ||
Coalitions Groups Against the Implementation | 11 | 32.4 |
Government Agency Representatives | 29 | 85.3 |
Health Professionals | 10 | 29.4 |
Data and Statistics Institutes | 14 | 41.2 |
Coalitions Groups In favor of the Implementation | 4 | 11.8 |
Others | 3 | 8.8 |